

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** Unknown  
**Gender:** Unknown  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 00/00/0000 00:00

**Autoimmune Movement Disorder Panel, Serum**

ARUP test code 3006206

Neuronal Antibody (Amphiphysin)

**High Positive \* (Ref Interval: Negative)**

INTERPRETIVE INFORMATION: Amphiphysin Antibody, IgG

Amphiphysin antibody is present in about 5 percent of patients with stiff-person syndrome and is found variably in other causes of paraneoplastic neurological syndrome (PNS). Amphiphysin antibody is mainly associated with small-cell lung cancer and breast tumors.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Purkinje Cell/Neuronal Nuclear IgG Scrn

**ANNA Detected \* (Ref Interval: None Detected)**

Antibodies detected, therefore IFA titer and Immunoblot testing to be performed.

INTERPRETIVE INFORMATION: Purkinje Cell/Neuronal Nuclear IgG Scrn

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

N-methyl-D-Aspartate Receptor Ab, Serum

**1:160 \* (Ref Interval: <1:10)**

Antibodies to NMDA were detected; titer was performed at an additional charge.

Clinical trials for anti-NMDA receptor encephalitis are currently underway (clinicaltrials.gov).

**H=High, L=Low, \*=Abnormal, C=Critical**

**INTERPRETIVE INFORMATION:** N-methyl-D-Aspartate Receptor Ab, Serum  
Anti-NMDA receptor IgG antibody is found in a subset of patients with autoimmune limbic encephalitis and may occur with or without associated tumor. Decreasing antibody levels may be associated with therapeutic response; therefore, clinical correlation must be strongly considered. A negative test result does not rule out a diagnosis of autoimmune limbic encephalitis.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**CASPR2 Ab IgG Screen by IFA, Serum**

**Detected \* (Ref Interval: <1:10)**

CASPR2 Antibody, IgG is detected. Titer results to follow.

**INTERPRETIVE INFORMATION:** CASPR2 Ab IgG by IFA, Serum

Contactin-associated protein-2 (CASPR2) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.

The presence of CASPR2 IgG antibody is associated with a wide spectrum of clinical manifestations, including acquired neuromyotonia, limbic encephalitis, painful neuropathy and Morvan syndrome. Tumors such as thymoma, small-cell lung cancer, and other rarer tumors may occur. The full-spectrum of clinical disorders and tumors associated with the CASPR2 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes contactin-associated protein-2 (CASPR2) transfected cell lines for the detection and semi-quantification of the CASPR2 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**LGI1 Ab IgG Screen by IFA, Serum**

**Detected \* (Ref Interval: <1:10)**

LGI1 Antibody, IgG is detected. Titer results to follow.

**H=High, L=Low, \*=Abnormal, C=Critical**

**INTERPRETIVE INFORMATION: LGI1 Ab IgG Screen by IFA, Serum**

Leucine-rich, glioma-inactivated 1 protein (LGI1) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.

The presence of LGI1 IgG antibody is mainly associated with limbic encephalitis, hyponatremia and myoclonic movements. LGI1 IgG antibody is rarely associated with tumors but may occur infrequently in Morvan syndrome, neuromyotonia, and idiopathic epilepsy. The full-spectrum of clinical disorders associated with the LGI1 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes leucine-rich, glioma-inactivated 1 protein (LGI1) transfected cell lines for the detection and semi-quantification of the LGI1 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**CV2.1 Antibody IgG Screen by IFA**

**Detected \* (Ref Interval: <1:10)**

CV2.1 Antibody, IgG is detected. Titer results to follow. Additional charges apply.

**INTERPRETIVE INFORMATION: CV2.1 Antibody IgG Screen by IFA**

CV2.1 antibodies aid in discriminating between chronic paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-CV2.1 is associated with small-cell lung cancer and thymoma.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**AMPA Receptor Ab IgG Screen, Serum**

**Detected \* (Ref Interval: <1:10)**

AMPA Antibody, IgG is detected. Titer results to follow.

**INTERPRETIVE INFORMATION: AMPA Receptor Ab IgG Screen, Serum**

Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) antibody is found in a subset of patients with autoimmune limbic encephalitis and may occur with or without associated tumor. Decreasing antibody levels may be associated with therapeutic response; therefore, clinical correlation must be strongly considered. A negative test result does not rule out a diagnosis of autoimmune encephalitis.

This indirect fluorescent antibody assay utilizes AMPAR transfected cell lines for the detection and semi-quantification of AMPAR IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**H=High, L=Low, \*=Abnormal, C=Critical**

**GABA-B Receptor Ab IgG Screen, Serum**

**Detected** \* (Ref Interval: <1:10)

GABA-BR Antibody, IgG is detected. Titer results to follow.

INTERPRETIVE INFORMATION: GABA Receptor Ab IgG Screen, Serum

Gamma-amino butyric acid receptor, type B (GABA-BR) antibody is found in a subset of patients with autoimmune limbic encephalitis and may occur with or without associated tumor. Decreasing antibody levels may be associated with therapeutic response; therefore, clinical correlation must be strongly considered. A negative test result does not rule out a diagnosis of autoimmune encephalitis.

This indirect fluorescent antibody assay utilizes GABA-BR transfected cell lines for the detection and semi-quantification of GABA-BR IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**SOX1 Antibody, IgG by Immunoblot, Serum**

**High Positive** \* (Ref Interval: Negative)

INTERPRETIVE INFORMATION: SOX1 Antibody, IgG by Immunoblot, Serum

SOX1 antibody is detected in patients with Lambert-Eaton myasthenic syndrome (LEMS) and in patients with paraneoplastic cerebellar degeneration (PCD), paraneoplastic and nonparaneoplastic neuropathy. SOX1 antibody is associated with small cell lung cancer. A negative test result does not rule out a diagnosis of LEMS or other causes of paraneoplastic neurological syndrome.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

**DPPX Ab IgG CBA IFA Screen, Serum**

**Detected** \* (Ref Interval: <1:10)

DPPX Antibody, IgG is detected. Titer results to follow.

INTERPRETIVE INFORMATION: DPPX Ab IgG CBA IFA Screen, Serum

Anti-DPPX IgG antibody is found in a subset of patients with autoimmune encephalitis and may occur with or without associated tumor. Decreasing antibody levels may be associated with therapeutic response; therefore, clinical correlation must be strongly considered. A negative test result does not rule out a diagnosis of autoimmune limbic encephalitis.

This indirect fluorescent antibody cell-based assay (CBA) utilizes dipeptidyl aminopeptidase-like protein 6 (DPPX) transfected cells for the detection of the DPPX IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**GABA-AR Ab IgG CBA-IFA Screen, Serum**

**Detected** \* (Ref Interval: <1:10)

H=High, L=Low, \*=Abnormal, C=Critical

GABA-AR Antibody, IgG is detected. Titer results to follow.

**INTERPRETIVE INFORMATION:** GABA-AR Ab IgG CBA-IFA Screen, Serum  
Gamma-aminobutyric acid receptor, type A (GABA-AR) antibody is found in a subset of patients with autoimmune encephalitis or autoimmune epilepsy and may occur with or without associated tumor. A negative test result does not rule out a diagnosis of autoimmune limbic encephalitis or autoimmune epilepsy. Interpretation of any antineural antibody test requires clinical correlation.

This indirect fluorescent antibody assay utilizes GABA-AR transfected cell lines for detection and semi-quantification of GABA-AR IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

ITPR1 Ab IgG CBA-IFA Screen, Serum

**Detected** \* (Ref Interval: <1:10)

ITPR1 Antibody, IgG is detected. Titer results to follow.

**INTERPRETIVE INFORMATION:** ITPR1 Ab IgG CBA-IFA Screen, Serum  
Inositol 1, 4, 5-trisphosphate receptor type 1 (ITPR1) antibody is found in a subset of patients with autoimmune cerebellar ataxia, encephalitis, neuropathy, or myelopathy and may occur with or without associated tumor. A negative test result does not rule out a diagnosis of autoimmune cerebellar ataxia or related autoimmune neurologic disorders. Interpretation of any antineural antibody test requires clinical correlation.

This indirect fluorescent antibody assay utilizes ITPR1 transfected cell lines for detection and semi-quantification of ITPR1 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

IgLON5 Ab IgG CBA-IFA Screen, Serum

**Detected** \* (Ref Interval: <1:10)

IgLON5 Antibody, IgG is detected. Titer results to follow.

**H=High, L=Low, \*=Abnormal, C=Critical**

**INTERPRETIVE INFORMATION:** IgLON5 Ab IgG CBA-IFA Screen, Serum  
IgLON Family Member 5 (IgLON5) antibody is found in a subset of patients with autoimmune encephalitis or other autoimmune neurologic/neurodegenerative disorders and may occur with or without associated tumor. A negative test result does not rule out a diagnosis of an autoimmune neurologic disorder. Interpretation of any antineural antibody test requires clinical correlation.

This indirect fluorescent antibody assay utilizes IgLON5 transfected cell lines for detection and semi-quantification of IgLON5 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

mGluR1 Ab IgG CBA-IFA Screen, Serum

**Detected \* (Ref Interval: <1:10)**

mGluR1 Antibody, IgG is detected. Titer results to follow.

**INTERPRETIVE INFORMATION:** mGluR1 Ab IgG CBA-IFA Screen, Serum

Metabotropic glutamate receptor 1 (mGluR1) antibody is found in a subset of patients with autoimmune cerebellar ataxia or autoimmune encephalitis and may occur with or without associated tumor. A negative test result does not rule out a diagnosis of autoimmune cerebellar ataxia or limbic encephalitis. Interpretation of any antineural antibody test requires clinical correlation.

This indirect fluorescent antibody assay utilizes mGluR1 transfected cell lines for detection and semi-quantification of mGluR1 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

P/Q-Type Calcium Channel Antibody

**50.0 pmol/L H (Ref Interval: 0.0-24.5)**

**INTERPRETIVE INFORMATION:** P/Q-Type Calcium Channel Antibody

0.0 to 24.5 pmol/L ..... Negative  
24.6 to 45.6 pmol/L ..... Indeterminate  
45.7 pmol/L or greater..... Positive

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Glutamic Acid Decarboxylase Antibody

**50.0 IU/mL H (Ref Interval: 0.0-5.0)**

**H=High, L=Low, \*=Abnormal, C=Critical**

**INTERPRETIVE INFORMATION: Glutamic Acid Decarboxylase Antibody**

A value greater than 5.0 IU/mL is considered positive for Glutamic Acid Decarboxylase Antibody (GAD Ab). This assay is intended for the semi-quantitative determination of the GAD Ab in human serum. Results should be interpreted within the context of clinical symptoms.

**Neuronal Nuclear Antibody (ANNA) IFA Titer, IgG (Do Not Use - Please Order (2007961) Paraneoplastic Antibodies (PCCA/ANNA) by IFA with Reflex to Titer and Immunoblot)**

ARUP test code 0050892

Neuronal Nuclear Ab (ANNA) IFA Titer IgG **1:160** \* (Ref Interval: <1:10)

**INTERPRETIVE INFORMATION: Neuronal Nuclear Ab (ANNA) IFA Titer IgG**

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**Contactin-Associated Protein-2 Antibody Titer, IgG by IFA, Serum (Reflex for 2009452 CASPR2 IGG Only - Not Orderable by Clients)**

ARUP test code 2009454

CASPR2 Ab IgG Titer by IFA, Serum **1:40** \* (Ref Interval: <1:10)

**INTERPRETIVE INFORMATION: CASPR2 Ab Titer IgG by IFA, Serum**

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**Leucine-Rich, Glioma-Inactivated Protein 1 Antibody Titer, IgG by IFA, Serum (Reflex for 2009456 LGI1 IGG Only - Not Orderable by Clients)**

ARUP test code 2009458

LGI1 Ab IgG Titer by IFA, Serum **1:80** \* (Ref Interval: <1:10)

**INTERPRETIVE INFORMATION: LGI1 Ab Titer IgG by IFA, Serum**

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**CV2.1 Antibody Titer, IgG (Reflex for 2013956 CV2.1SCRN Not orderable by clients)**

ARUP test code 2013957

CV2.1 Antibody IgG Titer by IFA **1:160** \* (Ref Interval: <1:10)

**H=High, L=Low, \*=Abnormal, C=Critical**

INTERPRETIVE INFORMATION: CV2.1 Antibody IgG Titer by IFA

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antibody Titer, IgG, Serum (Reflex of 3001260 AMPA SER - Not orderable by clients)**

ARUP test code 3001265

AMPA Receptor Ab IgG Titer, Serum

**1:80 \* (Ref Interval: <1:10)**

INTERPRETIVE INFORMATION: AMPA Receptor Ab IgG Titer, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**Gamma Aminobutyric Acid Receptor, Type B (GABA-BR) Antibody Titer, IgG, Serum (Reflex of 3001270 GABA SER - Not orderable by clients)**

ARUP test code 3001275

GABA-B Receptor Ab IgG Titer, Serum

**1:80 \* (Ref Interval: <1:10)**

INTERPRETIVE INFORMATION: GABA-B Receptor Ab IgG Titer, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**Neuronal Nuclear Antibodies (Hu, Ri, Yo, Tr/DNER) IgG by Immunoblot, Serum**

ARUP test code 3002917

Neuronal Nuclear Ab (Hu) IgG, IB, Serum

**High Positive \* (Ref Interval: Negative)**

H=High, L=Low, \*=Abnormal, C=Critical



**INTERPRETIVE INFORMATION:** Neuronal Nuclear Ab IgG, Immunoblot, Ser  
This test detects IgG antineuronal antibodies to Hu, Ri, Yo and Tr (DNER) antigens.

Antineuronal antibodies serve as markers that aid in discriminating between a true paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-Hu (antineuronal nuclear antibody, type I) is associated with small-cell lung cancer. Anti-Ri (antineuronal nuclear antibody, type II) is associated with neuroblastoma in children and with fallopian tube and breast cancer in adults. Anti-Yo (anti-Purkinje cell cytoplasmic antibody) is associated with ovarian and breast cancer. Anti-Tr(DNER) is associated with Hodgkin's lymphoma.

The presence of one or more of these antineuronal antibodies supports a clinical diagnosis of PND and should lead to a focused search for the underlying neoplasm.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Neuronal Nuclear Ab (Ri) IgG, IB, Serum

**High Positive \* (Ref Interval: Negative)**

**INTERPRETIVE INFORMATION:** Neuronal Nuclear Ab (Ri) IgG, IB, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Neuronal Nuclear Ab (Yo) IgG, IB, Serum

**Positive \* (Ref Interval: Negative)**

**INTERPRETIVE INFORMATION:** Neuronal Nuclear Ab (Yo) IgG, IB, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Neuronal Nuclear Ab (TR/DNER) IgG, IB

**Positive \* (Ref Interval: Negative)**

**INTERPRETIVE INFORMATION:** Neuronal Nuclear Ab (TR/DNER) IgG, IB

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**Dipeptidyl Aminopeptidase-Like Protein 6 (DPPX) Antibody Titer, IgG by IFA, Serum (Reflex for 3004359 DPPX SER Only - Not Orderable by Clients)**

ARUP test code 3004360

DPPX Ab IgG CBA IFA Titer, Serum

**1:320 \***

**(Ref Interval: <1:10)**

**H=High, L=Low, \*=Abnormal, C=Critical**

INTERPRETIVE INFORMATION: DPPX IgG Ab Titer, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**Gamma-Aminobutyric Acid Receptor, Type A (GABA-AR) Antibody Titer, IgG by CBA-IFA, Serum (Reflex of GABA-A SER - Not Orderable by Clients)**

ARUP test code 3006011

GABA-AR Ab IgG CBA-IFA Titer, Serum

**1:80** \* (Ref Interval: <1:10)

INTERPRETIVE INFORMATION: GABA-AR Ab IgG CBA-IFA Titer, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

**Inositol 1,4,5-Trisphosphate Receptor Type 1 (ITPR1) Antibody Titer, IgG by CBA-IFA, Serum (Reflex for ITPR1 SER Only - Not Orderable by Clients)**

ARUP test code 3006036

ITPR1 Ab IgG CBA-IFA Titer, Serum

**1:320** \* (Ref Interval: <1:10)

INTERPRETIVE INFORMATION: ITPR1 Ab IgG CBA-IFA Titer, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

**IgLON Family Member 5 (IgLON5) Antibody Titer, IgG by CBA-IFA, Serum (Reflex for IGLON5 SER Only - Not Orderable by Clients)**

ARUP test code 3006021

IgLON5 Ab IgG CBA-IFA Titer, Serum

**1:320** \* (Ref Interval: <1:10)

INTERPRETIVE INFORMATION: IgLON5 Ab IgG CBA-IFA Titer, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

**Metabotropic Glutamate Receptor 1 (mGluR1) Antibody Titer, IgG by CBA-IFA, Serum (Reflex for MGLUR1 SER Only - Not Orderable by Clients)**

ARUP test code 3006047

mGluR1 Ab IgG CBA-IFA Titer, Serum

**1:40** \* (Ref Interval: <1:10)

H=High, L=Low, \*=Abnormal, C=Critical

INTERPRETIVE INFORMATION: mGluR1 Ab IgG CBA-IFA Titer, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Neuronal Antibody (Amphiphysin)	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Purkinje Cell/Neuronal Nuclear IgG Scrn	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Neuronal Nuclear Ab (ANNA) IFA Titer IgG	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
N-methyl-D-Aspartate Receptor Ab, Serum	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CASPR2 Ab IgG Screen by IFA, Serum	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CASPR2 Ab IgG Titer by IFA, Serum	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
LG11 Ab IgG Screen by IFA, Serum	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
LG11 Ab IgG Titer by IFA, Serum	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CV2.1 Antibody IgG Screen by IFA	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CV2.1 Antibody IgG Titer by IFA	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
AMPA Receptor Ab IgG Screen, Serum	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
AMPA Receptor Ab IgG Titer, Serum	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
GABA-B Receptor Ab IgG Screen, Serum	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
GABA-B Receptor Ab IgG Titer, Serum	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Neuronal Nuclear Ab (Hu) IgG, IB, Serum	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Neuronal Nuclear Ab (Ri) IgG, IB, Serum	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Neuronal Nuclear Ab (Yo) IgG, IB, Serum	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Neuronal Nuclear Ab (TR/DNER) IgG, IB	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
SOX1 Antibody, IgG by Immunoblot, Serum	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
DPPX Ab IgG CBA IFA Screen, Serum	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
DPPX Ab IgG CBA IFA Titer, Serum	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
GABA-AR Ab IgG CBA-IFA Screen, Serum	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
GABA-AR Ab IgG CBA-IFA Titer, Serum	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
ITPR1 Ab IgG CBA-IFA Screen, Serum	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
ITPR1 Ab IgG CBA-IFA Titer, Serum	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
IgLON5 Ab IgG CBA-IFA Screen, Serum	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
IgLON5 Ab IgG CBA-IFA Titer, Serum	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
mGluR1 Ab IgG CBA-IFA Screen, Serum	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
mGluR1 Ab IgG CBA-IFA Titer, Serum	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
P/Q-Type Calcium Channel Antibody	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Glutamic Acid Decarboxylase Antibody	23-135-109174	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 23-135-109174  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 11 of 12 | Printed: 5/16/2023 1:15:24 PM  
4848

END OF CHART

---

**H=High, L=Low, \*=Abnormal, C=Critical**

---

*Unless otherwise indicated, testing performed at:*

ARUP LABORATORIES | 800-522-2787 | aruplab.com  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 23-135-109174  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 12 of 12 | Printed: 5/16/2023 1:15:24 PM  
4848